Biote 10-Q: Covenant Breach Waived, Cash Falls to $8.9M, Material Weakness Persists
BTMD is trading near its 52-week low of $0.99 (12% above the low).
Summary
Biote's Q3 10-Q shows a September 30 covenant breach that Truist only waived on November 4, cash down to $8.9 million from $24.1 million, and an internal-control material weakness still unremediated.
Key Events · Earnings and Guidance · BTMD
-
Covenant Breach Waived by Lenders
Biote was not in compliance with its Truist financial covenants as of September 30, 2026; the November 4 First Amendment waived the default and relaxed the leverage and fixed-charge tests through January 1, 2028.
-
New Liquidity and EBITDA Covenants
The amendment adds a $20.0 million minimum liquidity covenant and a minimum Consolidated EBITDA test starting at $29.75 million for the four quarters ended September 30, 2026, stepping to $23.0 million at December 31, 2026.
-
Revolver Cut, Pricing Tier Added
Available revolving commitments were reduced from $50.0 million to $35.0 million and a Level 3 tier at SOFR plus 3.25% was introduced once net leverage exceeds 3.75:1.00.
-
Cash Down to $8.9 Million
Cash and equivalents fell to $8.9 million at September 30, 2026 from $24.1 million at December 31, 2025, while the term loan balance rose to $124.2 million from $103.1 million after the May refinancing.
Analysis · BTMD · Life Sciences
The headline numbers were already out on November 4, but the 10-Q reveals the balance-sheet strain behind them. Biote was not in compliance with its Truist financial covenants at September 30, 2026 and only stayed in good standing because lenders signed a First Amendment on November 4 that waived the breach, loosened the leverage and fixed-charge tests through 2027, and added a $20.0 million minimum liquidity covenant plus a minimum EBITDA test. In exchange, the revolver was cut from $50.0 million to $35.0 million and a higher SOFR-plus-3.25% pricing tier was added. Cash has fallen to $8.9 million from $24.1 million at year-end, and the company still carries an unremediated material weakness in internal controls first identified years ago. Revenue fell 9.6% to $43.3 million and the nine-month period swung to a $4.2 million net loss from a $29.0 million profit, with $5.1 million of legal settlements in selling, general and administrative expense. The company says current cash, operating cash flow and revolver capacity fund operations for at least 12 months, but that depends on hitting the new EBITDA and liquidity thresholds.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BTMD was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.9M. The 52-week trading range was $0.99 to $2.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.